Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1994-6-23
pubmed:abstractText
Most published estimates of the costs of the epidemic of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) have been developed from the societal perspective, attempting to measure the burden of the epidemic to society in this country. Although societal cost analysis is well-developed, relatively little is known about many of the factors influencing the costs of the epidemic to business firms. The business community may bear a substantial portion of those costs in the form of health-related benefits provided to workers. Other effects of the epidemic in the workplace are related to fears and stigma associated with the illness. The author compares frameworks for analyzing the costs of the epidemic to the business community and to society. Societal costs include direct costs, the resources used in providing health care, and indirect costs, the resources lost to society as a result of the epidemic. Costs to business include illness-based employment costs, legal or administrative costs, prevention costs, perception-based employment costs, care giver costs, and nonmonetary costs. Not all societal costs are borne by business, and businesses may incur costs that are not traditionally measured from the societal perspective.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-10303496, http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-10311399, http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-1356925, http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-1739152, http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-1829547, http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-1833332, http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-1956975, http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-1983921, http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-2016653, http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-2063206, http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-2499556, http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-2671418, http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-2698447, http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-2887499, http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-3101123, http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-3104236, http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-3147234, http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-3277273, http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-3305998, http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-3941500, http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-828774, http://linkedlifedata.com/resource/pubmed/commentcorrection/8190854-8320787
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:status
MEDLINE
pubmed:issn
0033-3549
pubmed:author
pubmed:issnType
Print
pubmed:volume
109
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
311-8
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:articleTitle
Defining and measuring the costs of the HIV epidemic to business firms.
pubmed:affiliation
Centers for Disease Control and Prevention, Atlanta, GA.
pubmed:publicationType
Journal Article, Review